Cargando…

Chimeric antigen receptor T-cell therapy for multiple myeloma

Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zehua, Chen, Chen, Wang, Lei, Jia, Yongxu, Qin, Yanru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814974/ https://www.ncbi.nlm.nih.gov/pubmed/36618390 http://dx.doi.org/10.3389/fimmu.2022.1050522

Ejemplares similares

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement
por: Zhang, Ying, et al.
Publicado: (2021)

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma
por: Zhang, Qiqi, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
por: Padda, Jaskamal, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Case report: Hashimoto’s thyroiditis after CD19 chimeric antigen receptor T-cell therapy
por: Chen, Panpan, et al.
Publicado: (2022)

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
por: Xiao, Bu-Fan, et al.
Publicado: (2021)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

A compound chimeric antigen receptor strategy for targeting multiple myeloma
por: Chen, K H, et al.
Publicado: (2018)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
por: Kranz, Emiko, et al.
Publicado: (2022)

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
por: Kandra, Prameela, et al.
Publicado: (2022)

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
por: Zhang, Hao, et al.
Publicado: (2022)

Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2017)

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
por: Lin, Zili, et al.
Publicado: (2021)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy
por: Grywalska, Ewelina, et al.
Publicado: (2020)

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Chimeric antigen receptor T cells applied to solid tumors
por: Zhou, Zhongguo, et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017)

Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2019)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
por: Zheng, Diwei, et al.
Publicado: (2022)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013)

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
por: Kosti, Paris, et al.
Publicado: (2018)

B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
por: Zhang, Zheng, et al.
Publicado: (2023)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l0cdi8bpi369lvkiv00mirn8rl